Page last updated: 2024-10-30

memantine and Atrophy

memantine has been researched along with Atrophy in 8 studies

Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.

Research Excerpts

ExcerptRelevanceReference
"The primary objective of this study was to evaluate the rate of total brain atrophy (TBA) with serial magnetic resonance imaging (MRI), using the Brain Boundary Shift Integral (BBSI), in patients with probable Alzheimer's disease (AD) over the course of 52 weeks of treatment with memantine or placebo."9.16Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. ( Barkhof, F; Fox, NC; Lemming, O; Phul, R; Scheltens, P; Wilkinson, D, 2012)
"To study the effect of memantine on apathy, a common symptom of behavioral variant frontotemporal dementia (bvFTD)."7.79A case of apathy due to frontotemporal dementia responsive to memantine. ( Black, SE; Chow, TW; Graff-Guerrero, A; Houle, S; Links, KA; Pollock, BG; Wilson, AA, 2013)
"The finding that memantine protects adult visual neurons from transsynaptic atrophy in experimental glaucoma could have therapeutic value."7.73Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. ( Gupta, N; Kalichman, MW; Mizisin, AP; Weinreb, RN; Yücel, YH; Zhang, Q, 2006)
"The primary objective of this study was to evaluate the rate of total brain atrophy (TBA) with serial magnetic resonance imaging (MRI), using the Brain Boundary Shift Integral (BBSI), in patients with probable Alzheimer's disease (AD) over the course of 52 weeks of treatment with memantine or placebo."5.16Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. ( Barkhof, F; Fox, NC; Lemming, O; Phul, R; Scheltens, P; Wilkinson, D, 2012)
"To study the effect of memantine on apathy, a common symptom of behavioral variant frontotemporal dementia (bvFTD)."3.79A case of apathy due to frontotemporal dementia responsive to memantine. ( Black, SE; Chow, TW; Graff-Guerrero, A; Houle, S; Links, KA; Pollock, BG; Wilson, AA, 2013)
"The finding that memantine protects adult visual neurons from transsynaptic atrophy in experimental glaucoma could have therapeutic value."3.73Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. ( Gupta, N; Kalichman, MW; Mizisin, AP; Weinreb, RN; Yücel, YH; Zhang, Q, 2006)
"The diagnostic criteria of catatonia and frontotemporal dementia partly overlap."1.39Three patients with mood disorders showing catatonia and frontotemporal lobes atrophy. ( Arai, H; Iseki, E; Utumi, Y, 2013)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's6 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Utumi, Y1
Iseki, E1
Arai, H1
Borre, YE1
Panagaki, T1
Koelink, PJ1
Morgan, ME1
Hendriksen, H1
Garssen, J1
Kraneveld, AD1
Olivier, B1
Oosting, RS1
Ene-Stroescu, V1
Nguyen, T1
Waiblinger, BE1
Annweiler, C1
Wilkinson, D1
Fox, NC1
Barkhof, F1
Phul, R1
Lemming, O1
Scheltens, P1
Links, KA1
Black, SE1
Graff-Guerrero, A1
Wilson, AA1
Houle, S1
Pollock, BG1
Chow, TW1
Yücel, YH1
Gupta, N1
Zhang, Q1
Mizisin, AP1
Kalichman, MW1
Weinreb, RN1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A 1-year Randomised, Double-blind Placebo-controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients With Alzheimer's Disease[NCT00862940]Phase 4277 participants (Actual)Interventional2005-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Changes in Total Hippocampal Volume (HCV)

Estimated mean changes in total HCV (NCT00862940)
Timeframe: Baseline to 1 year

Interventionmm^3/year (Mean)
Memantine 10 mg Tablets Twice Daily-218
Placebo Tablets Twice Daily-220

Cognitive and Behavioural Outcomes: Controlled Oral Word Association Test (COWAT) Total Score

Adjusted mean change from baseline on cognitive and behavioural scores. COWAT: Verbal fluency test. The patient was asked to, during 1 minute, generate as many words as possible beginning with three pre-specified letters. The total score was calculated as the sum of acceptable words generated, with higher scores indicating lower cognitive impairment (NCT00862940)
Timeframe: Baseline to 1 year

InterventionScale scores (Least Squares Mean)
Memantine 10 mg Tablets Twice Daily0.78
Placebo Tablets Twice Daily-0.90

Cognitive and Behavioural Outcomes: Mini Mental State Examination (MMSE) Total Score

Adjusted mean change from baseline on cognitive and behavioural scores. MMSE: Brief, structured examination of mental status that assesses orientation, memory, attention, naming, comprehension, and praxis. The range is 0 to 30, with a lower score indicating a worse mental state (NCT00862940)
Timeframe: Baseline to 1 year

InterventionScale scores (Least Squares Mean)
Memantine 10 mg Tablets Twice Daily-0.50
Placebo Tablets Twice Daily-0.74

Total Brain Atrophy Rate Estimated Using Brain Boundary Shift Integral (BBSI)

Measures direct changes in total brain volume per visit interval (screening to Week 4, 42, or 52 or from Week 4 to Week 42 or 52) (NCT00862940)
Timeframe: Baseline to 1 year

InterventionmL/year (Mean)
Memantine 10 mg Tablets Twice Daily15.24
Placebo Tablets Twice Daily15.32

Reviews

1 review available for memantine and Atrophy

ArticleYear
[Vitamin D and Alzheimer's disease: from an intriguing idea to a therapeutic option].
    Biologie aujourd'hui, 2014, Volume: 208, Issue:1

    Topics: Acetylcholine; Alzheimer Disease; Amyloid; Animals; Anti-Inflammatory Agents; Antioxidants; Atrophy;

2014

Trials

1 trial available for memantine and Atrophy

ArticleYear
Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial.
    Journal of Alzheimer's disease : JAD, 2012, Volume: 29, Issue:2

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Atrophy; Brain; Cholinesterase Inh

2012

Other Studies

6 other studies available for memantine and Atrophy

ArticleYear
Three patients with mood disorders showing catatonia and frontotemporal lobes atrophy.
    Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2013, Volume: 13, Issue:4

    Topics: Aged; Atrophy; Catatonia; Combined Modality Therapy; Dopamine Agents; Electroconvulsive Therapy; Fem

2013
Neuroprotective and cognitive enhancing effects of a multi-targeted food intervention in an animal model of neurodegeneration and depression.
    Neuropharmacology, 2014, Volume: 79

    Topics: Animals; Atrophy; Cell Death; Cognition Disorders; Depressive Disorder; Disease Models, Animal; Hipp

2014
Successful treatment of catatonia in a young man with schizophrenia and progressive diffuse cerebral atrophy.
    The Journal of neuropsychiatry and clinical neurosciences, 2014,Winter, Volume: 26, Issue:1

    Topics: Adolescent; Amantadine; Anticonvulsants; Antiparkinson Agents; Antipsychotic Agents; Atrophy; Catato

2014
New developments in the treatment of Alzheimer's disease.
    The Journal of clinical psychiatry, 2009, Volume: 70, Issue:2

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Atrophy; Biomarkers; Brain; Choli

2009
A case of apathy due to frontotemporal dementia responsive to memantine.
    Neurocase, 2013, Volume: 19, Issue:3

    Topics: Aged; Apathy; Atrophy; Dopamine Agents; Follow-Up Studies; Frontal Lobe; Frontotemporal Dementia; Hu

2013
Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma.
    Archives of ophthalmology (Chicago, Ill. : 1960), 2006, Volume: 124, Issue:2

    Topics: Animals; Atrophy; Cell Count; Cytoprotection; Disease Models, Animal; Excitatory Amino Acid Antagoni

2006